Comparing Tandem Diabetes Care (NASDAQ:TNDM) & InVivo Therapeutics (NASDAQ:NVIV)

Tandem Diabetes Care (NASDAQ:TNDM) and InVivo Therapeutics (NASDAQ:NVIV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Insider and Institutional Ownership

88.6% of Tandem Diabetes Care shares are held by institutional investors. Comparatively, 0.5% of InVivo Therapeutics shares are held by institutional investors. 6.0% of Tandem Diabetes Care shares are held by insiders. Comparatively, 0.6% of InVivo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Tandem Diabetes Care has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, InVivo Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

Earnings & Valuation

This table compares Tandem Diabetes Care and InVivo Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tandem Diabetes Care $362.30 million 15.01 -$24.75 million ($0.22) -395.36
InVivo Therapeutics N/A N/A -$11.83 million N/A N/A

InVivo Therapeutics has lower revenue, but higher earnings than Tandem Diabetes Care.


This table compares Tandem Diabetes Care and InVivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tandem Diabetes Care -11.10% -10.98% -5.59%
InVivo Therapeutics N/A -124.37% -91.12%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tandem Diabetes Care and InVivo Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care 0 4 9 0 2.69
InVivo Therapeutics 0 0 0 0 N/A

Tandem Diabetes Care currently has a consensus price target of $118.62, indicating a potential upside of 36.37%. Given Tandem Diabetes Care’s higher probable upside, equities research analysts plainly believe Tandem Diabetes Care is more favorable than InVivo Therapeutics.


Tandem Diabetes Care beats InVivo Therapeutics on 7 of the 10 factors compared between the two stocks.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin delivery system with Basal-IQ Technology; t:slim X2 with control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Further, the company offers Sugarmate, a mobile app for people with diabetes who use insulin. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with's FREE daily email newsletter.